- Home
- CANF vs MTEK Comparison
CANF vs MTEK Comparison
Compare CANF & MTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- MTEK
- Stock Information
- Founded
- CANF 1994
- MTEK 2008
- Country
- CANF Israel
- MTEK Israel
- Employees
- CANF N/A
- MTEK N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- MTEK
- Sector
- CANF Health Care
- MTEK
- Exchange
- CANF Nasdaq
- MTEK Nasdaq
- Market Cap
- CANF 9.4M
- MTEK 20.2M
- IPO Year
- CANF N/A
- MTEK 2022
- Fundamental
- Price
- CANF $1.53
- MTEK $2.19
- Analyst Decision
- CANF Strong Buy
- MTEK
- Analyst Count
- CANF 2
- MTEK 0
- Target Price
- CANF $14.00
- MTEK N/A
- AVG Volume (30 Days)
- CANF 110.6K
- MTEK 46.6K
- Earning Date
- CANF 03-21-2025
- MTEK 03-20-2025
- Dividend Yield
- CANF N/A
- MTEK N/A
- EPS Growth
- CANF N/A
- MTEK N/A
- EPS
- CANF N/A
- MTEK N/A
- Revenue
- CANF $667,000.00
- MTEK $6,967,508.00
- Revenue This Year
- CANF $409.56
- MTEK N/A
- Revenue Next Year
- CANF N/A
- MTEK N/A
- P/E Ratio
- CANF N/A
- MTEK N/A
- Revenue Growth
- CANF N/A
- MTEK 246.50
- 52 Week Low
- CANF $1.29
- MTEK $1.13
- 52 Week High
- CANF $4.69
- MTEK $6.47
- Technical
- Relative Strength Index (RSI)
- CANF 42.09
- MTEK 36.33
- Support Level
- CANF $1.52
- MTEK $2.07
- Resistance Level
- CANF $1.76
- MTEK $2.38
- Average True Range (ATR)
- CANF 0.15
- MTEK 0.24
- MACD
- CANF -0.02
- MTEK 0.00
- Stochastic Oscillator
- CANF 13.56
- MTEK 14.12
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About MTEK Maris-Tech Ltd.
Maris Tech Ltd is a provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.